The company says that CGRP inhibitor Emgality (galcanezumab) hit all its objectives in the phase 3 CONQUER trial, which involved chronic and episodic migraine patients who had failed two to four ...

The Committee for Medicinal Products for Human Use (CHMP) said the single 106-patient study filed by Lilly to support the new marketing application for Emgality (galcanezumab) “did not show ...

The letter details that the advertisement for Ubrelvy 'makes false or misleading representations' about the drug, and might lead migraine patients ... Ajovy, Emgality and Aimovig - which are ...